Fevipiprant

Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma[1][2][3].

Product Specifications

CAS Number

[872365-14-5]

Product Name Alternative

QAW039; NVP-QAW039

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CRTH2 (GPR44) ; Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Fevipiprant.html

Concentration

10mM

Purity

99.63

Solubility

DMSO : ≥ 32 mg/mL

Smiles

O=C(O)CC1=C(C)N(CC2=CC=C(S(=O)(C)=O)C=C2C(F)(F)F)C3=NC=CC=C31

Molecular Formula

C19H17F3N2O4S

Molecular Weight

426.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Brightling C, et al. The pharmacology of the prostaglandin D2 receptor 2 (DP2) receptor antagonist, fevipiprant. Pulm Pharmacol Ther. 2021 Jun;68:102030.|[2]Lee HY, et al. Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma. Korean J Intern Med. 2020 May;35 (3) :619-629. |[3]Weintraub NL, et al. Role of prostaglandin D2 receptors in the pathogenesis of abdominal aortic aneurysm formation. Clin Sci (Lond) . 2022 Mar 18;136 (5) :309-321.